Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-690,400
Closed -$17.5M 597
2025
Q1
$17.5M Buy
690,400
+393,400
+132% +$10.3M 0.43% 73
2024
Q4
$7.88M Buy
+297,000
New +$8.06M 0.21% 149
2023
Q4
Sell
-350,000
Closed -$11.6M 438
2023
Q3
$11.6M Buy
+350,000
New +$12.4M 0.41% 77
2020
Q4
Sell
-177,388
Closed -$6.18M 459
2020
Q3
$6.18M Buy
+177,388
New +$6.22M 0.42% 78
2016
Q2
Sell
-158,100
Closed -$4.45M 394
2016
Q1
$4.45M Buy
+158,100
New +$4.52M 0.28% 101
2015
Q4
Sell
-484,840
Closed -$14.4M 285
2015
Q3
$14.4M Buy
484,840
+431,086
+802% +$13.8M 1.24% 15
2015
Q2
$1.71M Buy
+53,754
New +$1.75M 0.1% 172

Other funds holding PFE

J. Goldman & Co's PFE Position: Q1 2026 in Review

J. Goldman & Co opened a new position in Pfizer (PFE) in Q1 2026: 21,856 shares worth $614K. The stake represents 0.02% of the portfolio and ranks #482 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in PFE as recently as Q1 2025.

J. Goldman & Co first reported a position in PFE in Q2 2013 and has held it in 11 quarters since. The position peaked at $8.25M in Q4 2024. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • J. Goldman & Co held 21,856 shares of Pfizer worth $614K as of Q1 2026.
  • Pfizer was a new J. Goldman & Co position in Q1 2026.
  • Pfizer made up 0.02% of J. Goldman & Co's portfolio in Q1 2026, its #482 holding.
  • J. Goldman & Co first reported a position in Pfizer in Q2 2013 and has held it in 11 quarters since.
  • J. Goldman & Co's Pfizer position peaked at $8.25M in Q4 2024.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.